Vobarilizumab

Vobarilizumab (ALX-0061) is an anti-IL-6R monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis.

Vobarilizumab shows a preferential binding affinity for sIL-6R compared with mIL-6R^[2].
Vobarilizumab (0-10 nM) blocks the interaction of recombinant hIL-6 to recombinant hsIL-6R^[3].
Vobarilizumab (0-100 nM) blocks proliferation of the TF-1 cells^[3].

Vobarilizumab (0.4-10 mg/kg, i.v.) inhibits hIL-6-induced inflammation in cynomolgus monkey^[3].
Vobarilizumab (0.4-10 mg/kg, i.v.) shows a prolonged exposure through binding to serum albumin in cynomolgus monkeys^[3].

References:
[1]. Kerschbaumer A, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020 Jun;79(6):744-759.
[2]. M. Van Roy, et al. FRI0021 Alx-0061, an anti-IL-6r nanobody® for therapeutic use in rheumatoid arthritis, demonstrates in vitro a differential biological activity profile as compared to tocilizumab. Ann Rheum Dis. 2013. 72 (3).
[3]. Van Roy M, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17(1):135.